ID   ANAG_HUMAN              Reviewed;         743 AA.
AC   P54802;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=Alpha-N-acetylglucosaminidase;
DE            EC=3.2.1.50;
DE   AltName: Full=N-acetyl-alpha-glucosaminidase;
DE            Short=NAG;
DE   Contains:
DE     RecName: Full=Alpha-N-acetylglucosaminidase 82 kDa form;
DE   Contains:
DE     RecName: Full=Alpha-N-acetylglucosaminidase 77 kDa form;
DE   Flags: Precursor;
GN   Name=NAGLU; Synonyms=UFHSD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT GLY-737.
RC   TISSUE=Testis;
RX   PubMed=8650226; DOI=10.1073/pnas.93.12.6101;
RA   Zhao H.G., Li H.H., Bach G., Schmidtchen A., Neufeld E.F.;
RT   "The molecular basis of Sanfilippo syndrome type B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:6101-6105(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE,
RP   CHARACTERIZATION, AND VARIANT GLY-737.
RX   PubMed=8776591; DOI=10.1093/hmg/5.6.771;
RA   Weber B., Blanch L., Clements P.R., Scott H.S., Hopwood J.J.;
RT   "Cloning and expression of the gene involved in Sanfilippo B syndrome
RT   (mucopolysaccharidosis III B).";
RL   Hum. Mol. Genet. 5:771-777(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLY-737.
RX   PubMed=8703123; DOI=10.1007/s003359900206;
RA   Zhao Z., Yazdani A., Shen Y., Sun Z.S., Bailey J., Caskey C.T.,
RA   Lee C.C.;
RT   "Molecular dissection of a cosmid from a gene-rich region in 17q21 and
RT   characterization of a candidate gene for alpha-N-acetylglucosaminidase
RT   with two cDNA isoforms.";
RL   Mamm. Genome 7:686-690(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLY-737.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-532.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 24-743, AND GLYCOSYLATION AT
RP   ASN-261; ASN-272; ASN-435; ASN-503; ASN-526 AND ASN-532.
RA   Birrane G., Meiyappan M., Dassier A.;
RT   "Crystal structure of N-acetylglucosaminidase.";
RL   Submitted (JAN-2015) to the PDB data bank.
RN   [8]
RP   INVOLVEMENT IN CMT2V, AND VARIANT CMT2V THR-403.
RX   PubMed=25818867; DOI=10.1093/brain/awv074;
RA   Tetreault M., Gonzalez M., Dicaire M.J., Allard P., Gehring K.,
RA   Leblanc D., Leclerc N., Schondorf R., Mathieu J., Zuchner S.,
RA   Brais B.;
RT   "Adult-onset painful axonal polyneuropathy caused by a dominant NAGLU
RT   mutation.";
RL   Brain 138:1477-1483(2015).
RN   [9]
RP   VARIANTS MPS3B CYS-140; CYS-455; LEU-521; GLY-612; CYS-674 AND
RP   HIS-674.
RX   PubMed=9443875; DOI=10.1086/301682;
RA   Zhao H.G., Aronovich E.L., Whitley C.B.;
RT   "Genotype-phenotype correspondence in Sanfilippo syndrome type B.";
RL   Am. J. Hum. Genet. 62:53-63(1998).
RN   [10]
RP   VARIANTS MPS3B HIS-92; SER-115; CYS-140; LYS-153; LEU-358; VAL-664 AND
RP   ARG-682.
RX   PubMed=9443878; DOI=10.1086/301685;
RA   Schmidtchen A., Greenberg D., Zhao H.G., Li H.H., Huang Y., Tieu P.,
RA   Zhao H.-Z., Cheng S., Zhao Z., Whitley C.B., di Natale P.,
RA   Neufeld E.F.;
RT   "NAGLU mutations underlying Sanfilippo syndrome type B.";
RL   Am. J. Hum. Genet. 62:64-69(1998).
RN   [11]
RP   VARIANTS MPS3B CYS-48; CYS-140; CYS-234; ARG-268; LEU-521; TRP-565;
RP   PRO-591 AND LYS-705.
RX   PubMed=9832037; DOI=10.1136/jmg.35.11.910;
RA   Beesley C.E., Young E.P., Vellodi A., Winchester B.G.;
RT   "Identification of 12 novel mutations in the alpha-N-
RT   acetylglucosaminidase gene in 14 patients with Sanfilippo syndrome
RT   type B (mucopolysaccharidosis type IIIB).";
RL   J. Med. Genet. 35:910-914(1998).
RN   [12]
RP   VARIANTS MPS3B CYS-79; ARG-100; CYS-140; PHE-142 DEL; LEU-243;
RP   PHE-277; PRO-280; ARG-292; LYS-452; TRP-482; ARG-561; GLN-565; HIS-674
RP   AND LYS-705, AND VARIANT GLY-737.
RX   PubMed=9950362;
RA   Bunge S., Knigge A., Steglich C., Kleijer W.J., van Diggelen O.P.,
RA   Beck M., Gal A.;
RT   "Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18
RT   novel alpha-N-acetylglucosaminidase gene mutations.";
RL   J. Med. Genet. 36:28-31(1999).
RN   [13]
RP   VARIANTS MPS3B LEU-48; SER-69; PRO-227; ARG-248; ARG-292; PHE-334;
RP   SER-410; ARG-414; LEU-521; PRO-560; PRO-565; TRP-565; PHE-617;
RP   CYS-643; GLU-650; CYS-674 AND PRO-676, AND VARIANT GLY-737.
RX   PubMed=10094189; DOI=10.1038/sj.ejhg.5200242;
RA   Weber B., Guo X.-H., Kleijer W.J., van de Kamp J.J.P.,
RA   Poorthuis B.J.H.M., Hopwood J.J.;
RT   "Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic
RT   heterogeneity corresponds to the wide spectrum of clinical
RT   phenotypes.";
RL   Eur. J. Hum. Genet. 7:34-44(1999).
RN   [14]
RP   VARIANT MPS3B LEU-48, AND CHARACTERIZATION OF VARIANT MPS3B LEU-48.
RX   PubMed=11068184; DOI=10.1016/S0925-4439(00)00066-1;
RA   Yogalingam G., Weber B., Meehan J., Rogers J., Hopwood J.J.;
RT   "Mucopolysaccharidosis type IIIB: characterisation and expression of
RT   wild-type and mutant recombinant alpha-N-acetylglucosaminidase and
RT   relationship with sanfilippo phenotype in an attenuated patient.";
RL   Biochim. Biophys. Acta 1502:415-425(2000).
RN   [15]
RP   VARIANTS MPS3B PHE-35; ASP-82; CYS-140; CYS-156; CYS-234; ARG-292;
RP   GLY-501; TRP-520; TYR-534 AND CYS-649, AND CHARACTERIZATION OF
RP   VARIANTS MPS3B PHE-35; ASP-82; CYS-156; GLY-501; TRP-520; TYR-534 AND
RP   CYS-649.
RX   PubMed=11153910; DOI=10.1007/s004390000429;
RA   Tessitore A., Villani G.R.D., Di Domenico C., Filocamo M., Gatti R.,
RA   Di Natale P.;
RT   "Molecular defects in the alpha-N-acetylglucosaminidase gene in
RT   Italian Sanfilippo type B patients.";
RL   Hum. Genet. 107:568-576(2000).
RN   [16]
RP   VARIANTS MPS3B SER-79; CYS-234; GLY-474; TRP-565 AND PHE-658.
RX   PubMed=11286389; DOI=10.1023/A:1005627311402;
RA   Coll M.J., Anton C., Chabas A.;
RT   "Allelic heterogeneity in Spanish patients with Sanfilippo disease
RT   type B. Identification of eight new mutations.";
RL   J. Inherit. Metab. Dis. 24:83-84(2001).
RN   [17]
RP   VARIANTS MPS3B LYS-153; ARG-248; ILE-437 AND ARG-682.
RX   PubMed=11793481; DOI=10.1002/humu.9009;
RA   Emre S., Terzioglu M., Tokatli A., Coskun T., Ozalp I., Weber B.,
RA   Hopwood J.J.;
RT   "Sanfilippo syndrome in Turkey: identification of novel mutations in
RT   subtypes A and B.";
RL   Hum. Mutat. 19:184-185(2002).
RN   [18]
RP   VARIANTS MPS3B MET-241; LEU-314; TRP-482; PRO-565 AND TRP-565.
RX   PubMed=12202988; DOI=10.1007/s100380200070;
RA   Tanaka A., Kimura M., Lan H.T.N., Takaura N., Yamano T.;
RT   "Molecular analysis of the alpha-N-acetylglucosaminidase gene in seven
RT   Japanese patients from six unrelated families with
RT   mucopolysaccharidosis IIIB (Sanfilippo type B), including two novel
RT   mutations.";
RL   J. Hum. Genet. 47:484-487(2002).
RN   [19]
RP   VARIANTS MPS3B CYS-130; ARG-154; CYS-309; GLU-412 AND TRP-565, AND
RP   CHARACTERIZATION OF VARIANTS MPS3B CYS-130; ARG-154; CYS-309; GLU-412
RP   AND TRP-565.
RX   PubMed=11836372; DOI=10.1136/jmg.39.2.e3;
RA   Lee-Chen G.J., Lin S.P., Lin S.Z., Chuang C.K., Hsiao K.T.,
RA   Huang C.F., Lien W.C.;
RT   "Identification and characterisation of mutations underlying
RT   Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB).";
RL   J. Med. Genet. 39:E3-E3(2002).
RN   [20]
RP   VARIANTS MPS3B CYS-140; PRO-242; ARG-292; ARG-414; LYS-446; LYS-452;
RP   GLN-482 AND LEU-516, AND CHARACTERIZATION OF VARIANTS MPS3B PRO-242;
RP   ARG-414; LYS-446; GLN-482 AND LEU-516.
RX   PubMed=14984474; DOI=10.1111/j.0009-9163.2004.00210.x;
RA   Beesley C., Moraitou M., Winchester B., Schulpis K., Dimitriou E.,
RA   Michelakakis H.;
RT   "Sanfilippo B syndrome: molecular defects in Greek patients.";
RL   Clin. Genet. 65:143-149(2004).
RN   [21]
RP   VARIANT MPS3B PRO-565.
RX   PubMed=15933803; DOI=10.1007/s10038-005-0258-4;
RA   Chinen Y., Tohma T., Izumikawa Y., Uehara H., Ohta T.;
RT   "Sanfilippo type B syndrome: five patients with an R565P homozygous
RT   mutation in the alpha-N-acetylglucosaminidase gene from the Okinawa
RT   islands in Japan.";
RL   J. Hum. Genet. 50:357-359(2005).
RN   [22]
RP   VARIANTS MPS3B TRP-38; GLY-77; CYS-79; CYS-130; PRO-246; CYS-309;
RP   CYS-335; ARG-414; LYS-452; TRP-482; TRP-520; LEU-521 AND TRP-565, AND
RP   CHARACTERIZATION OF VARIANTS MPS3B TRP-38; GLY-77 AND CYS-335.
RX   PubMed=16151907; DOI=10.1007/s10545-005-0093-y;
RA   Beesley C.E., Jackson M., Young E.P., Vellodi A., Winchester B.G.;
RT   "Molecular defects in Sanfilippo syndrome type B
RT   (mucopolysaccharidosis IIIB).";
RL   J. Inherit. Metab. Dis. 28:759-767(2005).
CC   -!- FUNCTION: Involved in the degradation of heparan sulfate.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal non-reducing N-acetyl-
CC       D-glucosamine residues in N-acetyl-alpha-D-glucosaminides.
CC   -!- SUBUNIT: Monomer and homodimer.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- TISSUE SPECIFICITY: Liver, ovary, peripheral blood leukocytes,
CC       testis, prostate, spleen, colon, lung, placenta and kidney.
CC   -!- DISEASE: Mucopolysaccharidosis 3B (MPS3B) [MIM:252920]: A form of
CC       mucopolysaccharidosis type 3, an autosomal recessive lysosomal
CC       storage disease due to impaired degradation of heparan sulfate.
CC       MPS3 is characterized by severe central nervous system
CC       degeneration, but only mild somatic disease. Onset of clinical
CC       features usually occurs between 2 and 6 years; severe neurologic
CC       degeneration occurs in most patients between 6 and 10 years of
CC       age, and death occurs typically during the second or third decade
CC       of life. {ECO:0000269|PubMed:10094189,
CC       ECO:0000269|PubMed:11068184, ECO:0000269|PubMed:11153910,
CC       ECO:0000269|PubMed:11286389, ECO:0000269|PubMed:11793481,
CC       ECO:0000269|PubMed:11836372, ECO:0000269|PubMed:12202988,
CC       ECO:0000269|PubMed:14984474, ECO:0000269|PubMed:15933803,
CC       ECO:0000269|PubMed:16151907, ECO:0000269|PubMed:9443875,
CC       ECO:0000269|PubMed:9443878, ECO:0000269|PubMed:9832037,
CC       ECO:0000269|PubMed:9950362}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 2V (CMT2V) [MIM:616491]: An
CC       axonal form of Charcot-Marie-Tooth disease, a disorder of the
CC       peripheral nervous system, characterized by progressive weakness
CC       and atrophy, initially of the peroneal muscles and later of the
CC       distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited)
CC       and primary peripheral axonal neuropathies (CMT2). Neuropathies of
CC       the CMT2 group are characterized by signs of axonal degeneration
CC       in the absence of obvious myelin alterations, normal or slightly
CC       reduced nerve conduction velocities, and progressive distal muscle
CC       weakness and atrophy. CMT2V is an autosomal dominant sensory
CC       neuropathy with late onset. The main clinical feature is recurrent
CC       leg pain that progresses to constant painful paraesthesias in the
CC       feet and later the hands. As it evolves, some patients develop a
CC       mild sensory ataxia. {ECO:0000269|PubMed:25818867}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 89 family.
CC       {ECO:0000305}.
CC   -!- CAUTION: A MPS3B mutation at position 100 was erroneously reported
CC       (PubMed:9950362) as an amino acid change from Arg to His. The
CC       right amino acid change is from His to Arg.
CC       {ECO:0000305|PubMed:9950362}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U43572; AAC50512.1; -; Genomic_DNA.
DR   EMBL; U43573; AAC50513.1; -; mRNA.
DR   EMBL; U40846; AAB06188.1; -; mRNA.
DR   EMBL; L78464; AAB36604.1; -; mRNA.
DR   EMBL; AC067852; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC053991; AAH53991.1; -; mRNA.
DR   CCDS; CCDS11427.1; -.
DR   PIR; G02270; G02270.
DR   RefSeq; NP_000254.2; NM_000263.3.
DR   UniGene; Hs.50727; -.
DR   PDB; 4XWH; X-ray; 2.32 A; A=24-743.
DR   PDBsum; 4XWH; -.
DR   ProteinModelPortal; P54802; -.
DR   SMR; P54802; -.
DR   BioGrid; 110750; 23.
DR   STRING; 9606.ENSP00000225927; -.
DR   DrugBank; DB00141; N-Acetyl-D-glucosamine.
DR   CAZy; GH89; Glycoside Hydrolase Family 89.
DR   iPTMnet; P54802; -.
DR   PhosphoSitePlus; P54802; -.
DR   UniCarbKB; P54802; -.
DR   BioMuta; NAGLU; -.
DR   DMDM; 317373322; -.
DR   EPD; P54802; -.
DR   MaxQB; P54802; -.
DR   PaxDb; P54802; -.
DR   PeptideAtlas; P54802; -.
DR   PRIDE; P54802; -.
DR   TopDownProteomics; P54802; -.
DR   Ensembl; ENST00000225927; ENSP00000225927; ENSG00000108784.
DR   GeneID; 4669; -.
DR   KEGG; hsa:4669; -.
DR   UCSC; uc002hzv.4; human.
DR   CTD; 4669; -.
DR   DisGeNET; 4669; -.
DR   GeneCards; NAGLU; -.
DR   H-InvDB; HIX0202517; -.
DR   HGNC; HGNC:7632; NAGLU.
DR   HPA; HPA038815; -.
DR   MalaCards; NAGLU; -.
DR   MIM; 252920; phenotype.
DR   MIM; 609701; gene.
DR   MIM; 616491; phenotype.
DR   neXtProt; NX_P54802; -.
DR   OpenTargets; ENSG00000108784; -.
DR   Orphanet; 79270; Sanfilippo syndrome type B.
DR   PharmGKB; PA31437; -.
DR   eggNOG; KOG2233; Eukaryota.
DR   eggNOG; ENOG410XNMK; LUCA.
DR   GeneTree; ENSGT00390000005900; -.
DR   HOGENOM; HOG000214539; -.
DR   HOVERGEN; HBG004225; -.
DR   InParanoid; P54802; -.
DR   KO; K01205; -.
DR   OMA; VAKPEYM; -.
DR   OrthoDB; EOG091G02QN; -.
DR   PhylomeDB; P54802; -.
DR   TreeFam; TF300689; -.
DR   BRENDA; 3.2.1.50; 2681.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   ChiTaRS; NAGLU; human.
DR   GenomeRNAi; 4669; -.
DR   PRO; PR:P54802; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108784; -.
DR   CleanEx; HS_NAGLU; -.
DR   ExpressionAtlas; P54802; baseline and differential.
DR   Genevisible; P54802; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0004561; F:alpha-N-acetylglucosaminidase activity; TAS:Reactome.
DR   GO; GO:0021680; P:cerebellar Purkinje cell layer development; IEA:Ensembl.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0060119; P:inner ear receptor cell development; IEA:Ensembl.
DR   GO; GO:0045475; P:locomotor rhythm; IEA:Ensembl.
DR   GO; GO:0007040; P:lysosome organization; IEA:Ensembl.
DR   GO; GO:0042474; P:middle ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR007781; NAGLU.
DR   InterPro; IPR024732; NAGLU_C.
DR   InterPro; IPR024240; NAGLU_N.
DR   InterPro; IPR024733; NAGLU_tim-barrel.
DR   PANTHER; PTHR12872; PTHR12872; 1.
DR   Pfam; PF05089; NAGLU; 1.
DR   Pfam; PF12972; NAGLU_C; 1.
DR   Pfam; PF12971; NAGLU_N; 1.
DR   SUPFAM; SSF51445; SSF51445; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Charcot-Marie-Tooth disease; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein;
KW   Glycosidase; Hydrolase; Lysosome; Mucopolysaccharidosis;
KW   Neurodegeneration; Neuropathy; Polymorphism; Reference proteome;
KW   Signal.
FT   SIGNAL        1     23
FT   CHAIN        24    743       Alpha-N-acetylglucosaminidase 82 kDa
FT                                form.
FT                                /FTId=PRO_0000020728.
FT   CHAIN        59    743       Alpha-N-acetylglucosaminidase 77 kDa
FT                                form.
FT                                /FTId=PRO_0000020729.
FT   COMPBIAS     68     71       Poly-Gly.
FT   COMPBIAS     84     87       Poly-Ala.
FT   CARBOHYD    261    261       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4XWH,
FT                                ECO:0000269|Ref.7}.
FT   CARBOHYD    272    272       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4XWH,
FT                                ECO:0000269|Ref.7}.
FT   CARBOHYD    435    435       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4XWH,
FT                                ECO:0000269|Ref.7}.
FT   CARBOHYD    503    503       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4XWH,
FT                                ECO:0000269|Ref.7}.
FT   CARBOHYD    526    526       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4XWH,
FT                                ECO:0000269|Ref.7}.
FT   CARBOHYD    532    532       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4XWH,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|Ref.7}.
FT   VARIANT      35     35       L -> F (in MPS3B; no enzyme activity;
FT                                synthesizes a polypeptide with a
FT                                molecular size similar to that of the
FT                                wild-type).
FT                                {ECO:0000269|PubMed:11153910}.
FT                                /FTId=VAR_054699.
FT   VARIANT      38     38       R -> W (in MPS3B; decreases the enzyme
FT                                activity markedly).
FT                                {ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054700.
FT   VARIANT      48     48       F -> C (in MPS3B; dbSNP:rs867910252).
FT                                {ECO:0000269|PubMed:9832037}.
FT                                /FTId=VAR_054701.
FT   VARIANT      48     48       F -> L (in MPS3B; associated with a
FT                                partially degraded polypeptide in a 16-
FT                                hour chase experiment suggesting that L-
FT                                48 NAGLU affects the processing and
FT                                stability of the gene; some L-48 NAGLU is
FT                                being correctly sorted to the lysosomal
FT                                compartment; dbSNP:rs104894599).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:11068184}.
FT                                /FTId=VAR_025489.
FT   VARIANT      69     69       G -> S (in MPS3B).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054702.
FT   VARIANT      77     77       V -> G (in MPS3B; decreases the enzyme
FT                                activity markedly).
FT                                {ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054703.
FT   VARIANT      79     79       G -> C (in MPS3B).
FT                                {ECO:0000269|PubMed:16151907,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008979.
FT   VARIANT      79     79       G -> S (in MPS3B).
FT                                {ECO:0000269|PubMed:11286389}.
FT                                /FTId=VAR_054704.
FT   VARIANT      82     82       G -> D (in MPS3B; no enzyme activity;
FT                                synthesizes a polypeptide with a
FT                                molecular size similar to that of the
FT                                wild-type).
FT                                {ECO:0000269|PubMed:11153910}.
FT                                /FTId=VAR_054705.
FT   VARIANT      92     92       Y -> H (in MPS3B).
FT                                {ECO:0000269|PubMed:9443878}.
FT                                /FTId=VAR_005007.
FT   VARIANT     100    100       H -> R (in MPS3B).
FT                                {ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008980.
FT   VARIANT     115    115       P -> S (in MPS3B; dbSNP:rs758785463).
FT                                {ECO:0000269|PubMed:9443878}.
FT                                /FTId=VAR_005008.
FT   VARIANT     130    130       R -> C (in MPS3B; does not yield active
FT                                enzyme). {ECO:0000269|PubMed:11836372,
FT                                ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054706.
FT   VARIANT     140    140       Y -> C (in MPS3B; dbSNP:rs753520553).
FT                                {ECO:0000269|PubMed:11153910,
FT                                ECO:0000269|PubMed:14984474,
FT                                ECO:0000269|PubMed:9443875,
FT                                ECO:0000269|PubMed:9443878,
FT                                ECO:0000269|PubMed:9832037,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_005009.
FT   VARIANT     142    142       Missing (in MPS3B).
FT                                {ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008981.
FT   VARIANT     153    153       E -> K (in MPS3B).
FT                                {ECO:0000269|PubMed:11793481,
FT                                ECO:0000269|PubMed:9443878}.
FT                                /FTId=VAR_005010.
FT   VARIANT     154    154       I -> R (in MPS3B; does not yield active
FT                                enzyme; dbSNP:rs770684838).
FT                                {ECO:0000269|PubMed:11836372}.
FT                                /FTId=VAR_054707.
FT   VARIANT     156    156       W -> C (in MPS3B; no enzyme activity;
FT                                synthesizes a polypeptide with a
FT                                molecular size similar to that of the
FT                                wild-type).
FT                                {ECO:0000269|PubMed:11153910}.
FT                                /FTId=VAR_054708.
FT   VARIANT     227    227       H -> P (in MPS3B; dbSNP:rs747155746).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054709.
FT   VARIANT     234    234       R -> C (in MPS3B; dbSNP:rs104894601).
FT                                {ECO:0000269|PubMed:11153910,
FT                                ECO:0000269|PubMed:11286389,
FT                                ECO:0000269|PubMed:9832037}.
FT                                /FTId=VAR_054710.
FT   VARIANT     241    241       V -> M (in MPS3B).
FT                                {ECO:0000269|PubMed:12202988}.
FT                                /FTId=VAR_054711.
FT   VARIANT     242    242       L -> P (in MPS3B; no enzyme activity).
FT                                {ECO:0000269|PubMed:14984474}.
FT                                /FTId=VAR_054712.
FT   VARIANT     243    243       P -> L (in MPS3B).
FT                                {ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008982.
FT   VARIANT     246    246       A -> P (in MPS3B; produces 12.7% residual
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054713.
FT   VARIANT     248    248       H -> R (in MPS3B).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:11793481}.
FT                                /FTId=VAR_054714.
FT   VARIANT     268    268       W -> R (in MPS3B).
FT                                {ECO:0000269|PubMed:9832037}.
FT                                /FTId=VAR_054715.
FT   VARIANT     277    277       C -> F (in MPS3B).
FT                                {ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008983.
FT   VARIANT     280    280       L -> P (in MPS3B).
FT                                {ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008984.
FT   VARIANT     292    292       G -> R (in MPS3B).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:11153910,
FT                                ECO:0000269|PubMed:14984474,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008985.
FT   VARIANT     309    309       Y -> C (in MPS3B; does not yield active
FT                                enzyme). {ECO:0000269|PubMed:11836372,
FT                                ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054716.
FT   VARIANT     314    314       F -> L (in MPS3B; dbSNP:rs104894600).
FT                                {ECO:0000269|PubMed:12202988}.
FT                                /FTId=VAR_025490.
FT   VARIANT     334    334       V -> F (in MPS3B; dbSNP:rs749140168).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054717.
FT   VARIANT     335    335       Y -> C (in MPS3B; decreases the enzyme
FT                                activity markedly; dbSNP:rs768918822).
FT                                {ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054718.
FT   VARIANT     358    358       P -> L (in MPS3B; dbSNP:rs368687817).
FT                                {ECO:0000269|PubMed:9443878}.
FT                                /FTId=VAR_005011.
FT   VARIANT     403    403       I -> T (in CMT2V; dbSNP:rs796052122).
FT                                {ECO:0000269|PubMed:25818867}.
FT                                /FTId=VAR_074607.
FT   VARIANT     410    410       F -> S (in MPS3B; dbSNP:rs574688121).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054719.
FT   VARIANT     412    412       G -> E (in MPS3B; does not yield active
FT                                enzyme). {ECO:0000269|PubMed:11836372}.
FT                                /FTId=VAR_054720.
FT   VARIANT     414    414       H -> R (in MPS3B; no enzyme activity;
FT                                dbSNP:rs768814260).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:14984474,
FT                                ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054721.
FT   VARIANT     437    437       T -> I (in MPS3B).
FT                                {ECO:0000269|PubMed:11793481}.
FT                                /FTId=VAR_054722.
FT   VARIANT     446    446       E -> K (in MPS3B; no enzyme activity;
FT                                dbSNP:rs114625063).
FT                                {ECO:0000269|PubMed:14984474}.
FT                                /FTId=VAR_054723.
FT   VARIANT     452    452       E -> K (in MPS3B).
FT                                {ECO:0000269|PubMed:14984474,
FT                                ECO:0000269|PubMed:16151907,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008986.
FT   VARIANT     455    455       Y -> C (in MPS3B; dbSNP:rs375103824).
FT                                {ECO:0000269|PubMed:9443875}.
FT                                /FTId=VAR_054724.
FT   VARIANT     474    474       W -> G (in MPS3B).
FT                                {ECO:0000269|PubMed:11286389}.
FT                                /FTId=VAR_054725.
FT   VARIANT     482    482       R -> Q (in MPS3B; no enzyme activity;
FT                                dbSNP:rs200909691).
FT                                {ECO:0000269|PubMed:14984474}.
FT                                /FTId=VAR_054726.
FT   VARIANT     482    482       R -> W (in MPS3B; dbSNP:rs104894596).
FT                                {ECO:0000269|PubMed:12202988,
FT                                ECO:0000269|PubMed:16151907,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008987.
FT   VARIANT     501    501       V -> G (in MPS3B; no enzyme activity;
FT                                synthesizes a polypeptide with a
FT                                molecular size similar to that of the
FT                                wild-type).
FT                                {ECO:0000269|PubMed:11153910}.
FT                                /FTId=VAR_054727.
FT   VARIANT     516    516       P -> L (in MPS3B; no enzyme activity;
FT                                dbSNP:rs773054539).
FT                                {ECO:0000269|PubMed:14984474}.
FT                                /FTId=VAR_054728.
FT   VARIANT     520    520       R -> W (in MPS3B; no enzyme activity;
FT                                synthesizes a polypeptide with a
FT                                molecular size similar to that of the
FT                                wild-type). {ECO:0000269|PubMed:11153910,
FT                                ECO:0000269|PubMed:16151907}.
FT                                /FTId=VAR_054729.
FT   VARIANT     521    521       P -> L (in MPS3B; accounts for
FT                                approximately 6% of mutations in
FT                                Australasian patients with MPS3B;
FT                                dbSNP:rs104894595).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:16151907,
FT                                ECO:0000269|PubMed:9443875,
FT                                ECO:0000269|PubMed:9832037}.
FT                                /FTId=VAR_025491.
FT   VARIANT     534    534       S -> Y (in MPS3B; no enzyme activity;
FT                                synthesizes a polypeptide with a
FT                                molecular size similar to that of the
FT                                wild-type).
FT                                {ECO:0000269|PubMed:11153910}.
FT                                /FTId=VAR_054730.
FT   VARIANT     560    560       L -> P (in MPS3B).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054731.
FT   VARIANT     561    561       L -> R (in MPS3B).
FT                                {ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008988.
FT   VARIANT     565    565       R -> P (in MPS3B; does not yield active
FT                                enzyme; dbSNP:rs104894598).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:12202988,
FT                                ECO:0000269|PubMed:15933803}.
FT                                /FTId=VAR_025492.
FT   VARIANT     565    565       R -> Q (in MPS3B; dbSNP:rs104894598).
FT                                {ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008989.
FT   VARIANT     565    565       R -> W (in MPS3B; accounts for
FT                                approximately 6% of the mutant alleles in
FT                                Australasian patients with MPS3B;
FT                                dbSNP:rs104894597).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:11286389,
FT                                ECO:0000269|PubMed:11836372,
FT                                ECO:0000269|PubMed:12202988,
FT                                ECO:0000269|PubMed:16151907,
FT                                ECO:0000269|PubMed:9832037}.
FT                                /FTId=VAR_025493.
FT   VARIANT     591    591       L -> P (in MPS3B).
FT                                {ECO:0000269|PubMed:9832037}.
FT                                /FTId=VAR_054732.
FT   VARIANT     612    612       S -> G (in MPS3B; dbSNP:rs148881970).
FT                                {ECO:0000269|PubMed:9443875}.
FT                                /FTId=VAR_054733.
FT   VARIANT     617    617       L -> F (in MPS3B).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054734.
FT   VARIANT     643    643       R -> C (in MPS3B; accounts for
FT                                approximately 20% of MPS3B alleles in a
FT                                Dutch patient group; dbSNP:rs104894594).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_025494.
FT   VARIANT     643    643       R -> H (in MPS3B; dbSNP:rs104894593).
FT                                /FTId=VAR_005012.
FT   VARIANT     649    649       W -> C (in MPS3B; no enzyme activity;
FT                                synthesizes a polypeptide with a
FT                                molecular size similar to that of the
FT                                wild-type).
FT                                {ECO:0000269|PubMed:11153910}.
FT                                /FTId=VAR_054735.
FT   VARIANT     650    650       G -> E (in MPS3B; dbSNP:rs527236037).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054736.
FT   VARIANT     658    658       Y -> F (in MPS3B).
FT                                {ECO:0000269|PubMed:11286389}.
FT                                /FTId=VAR_054737.
FT   VARIANT     664    664       A -> V (in MPS3B; dbSNP:rs746006696).
FT                                {ECO:0000269|PubMed:9443878}.
FT                                /FTId=VAR_005013.
FT   VARIANT     674    674       R -> C (in MPS3B; dbSNP:rs763299645).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:9443875}.
FT                                /FTId=VAR_054738.
FT   VARIANT     674    674       R -> H (in MPS3B; dbSNP:rs104894590).
FT                                {ECO:0000269|PubMed:9443875,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_005014.
FT   VARIANT     676    676       R -> P (in MPS3B).
FT                                {ECO:0000269|PubMed:10094189}.
FT                                /FTId=VAR_054739.
FT   VARIANT     682    682       L -> R (in MPS3B).
FT                                {ECO:0000269|PubMed:11793481,
FT                                ECO:0000269|PubMed:9443878}.
FT                                /FTId=VAR_005015.
FT   VARIANT     705    705       E -> K (in MPS3B).
FT                                {ECO:0000269|PubMed:9832037,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008990.
FT   VARIANT     737    737       R -> G (in dbSNP:rs86312).
FT                                {ECO:0000269|PubMed:10094189,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8650226,
FT                                ECO:0000269|PubMed:8703123,
FT                                ECO:0000269|PubMed:8776591,
FT                                ECO:0000269|PubMed:9950362}.
FT                                /FTId=VAR_008991.
FT   CONFLICT    551    551       A -> L (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    553    553       S -> L (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        25     40       {ECO:0000244|PDB:4XWH}.
FT   HELIX        42     45       {ECO:0000244|PDB:4XWH}.
FT   STRAND       48     52       {ECO:0000244|PDB:4XWH}.
FT   HELIX        54     56       {ECO:0000244|PDB:4XWH}.
FT   STRAND       64     69       {ECO:0000244|PDB:4XWH}.
FT   STRAND       75     81       {ECO:0000244|PDB:4XWH}.
FT   HELIX        82     95       {ECO:0000244|PDB:4XWH}.
FT   STRAND      100    102       {ECO:0000244|PDB:4XWH}.
FT   STRAND      105    107       {ECO:0000244|PDB:4XWH}.
FT   STRAND      121    124       {ECO:0000244|PDB:4XWH}.
FT   STRAND      128    132       {ECO:0000244|PDB:4XWH}.
FT   HELIX       137    140       {ECO:0000244|PDB:4XWH}.
FT   HELIX       147    159       {ECO:0000244|PDB:4XWH}.
FT   STRAND      164    166       {ECO:0000244|PDB:4XWH}.
FT   HELIX       171    182       {ECO:0000244|PDB:4XWH}.
FT   HELIX       186    192       {ECO:0000244|PDB:4XWH}.
FT   HELIX       196    198       {ECO:0000244|PDB:4XWH}.
FT   HELIX       199    203       {ECO:0000244|PDB:4XWH}.
FT   HELIX       216    235       {ECO:0000244|PDB:4XWH}.
FT   STRAND      239    243       {ECO:0000244|PDB:4XWH}.
FT   STRAND      247    249       {ECO:0000244|PDB:4XWH}.
FT   HELIX       253    256       {ECO:0000244|PDB:4XWH}.
FT   STRAND      262    264       {ECO:0000244|PDB:4XWH}.
FT   TURN        273    275       {ECO:0000244|PDB:4XWH}.
FT   STRAND      279    281       {ECO:0000244|PDB:4XWH}.
FT   HELIX       287    303       {ECO:0000244|PDB:4XWH}.
FT   STRAND      307    310       {ECO:0000244|PDB:4XWH}.
FT   HELIX       324    339       {ECO:0000244|PDB:4XWH}.
FT   STRAND      346    350       {ECO:0000244|PDB:4XWH}.
FT   HELIX       352    356       {ECO:0000244|PDB:4XWH}.
FT   TURN        358    360       {ECO:0000244|PDB:4XWH}.
FT   HELIX       363    370       {ECO:0000244|PDB:4XWH}.
FT   STRAND      377    382       {ECO:0000244|PDB:4XWH}.
FT   TURN        383    387       {ECO:0000244|PDB:4XWH}.
FT   HELIX       391    393       {ECO:0000244|PDB:4XWH}.
FT   HELIX       395    398       {ECO:0000244|PDB:4XWH}.
FT   STRAND      402    406       {ECO:0000244|PDB:4XWH}.
FT   HELIX       420    432       {ECO:0000244|PDB:4XWH}.
FT   STRAND      438    443       {ECO:0000244|PDB:4XWH}.
FT   HELIX       452    461       {ECO:0000244|PDB:4XWH}.
FT   HELIX       471    483       {ECO:0000244|PDB:4XWH}.
FT   HELIX       488    499       {ECO:0000244|PDB:4XWH}.
FT   TURN        500    502       {ECO:0000244|PDB:4XWH}.
FT   HELIX       516    518       {ECO:0000244|PDB:4XWH}.
FT   HELIX       533    545       {ECO:0000244|PDB:4XWH}.
FT   HELIX       547    550       {ECO:0000244|PDB:4XWH}.
FT   HELIX       554    584       {ECO:0000244|PDB:4XWH}.
FT   HELIX       588    600       {ECO:0000244|PDB:4XWH}.
FT   HELIX       602    610       {ECO:0000244|PDB:4XWH}.
FT   HELIX       614    616       {ECO:0000244|PDB:4XWH}.
FT   HELIX       618    628       {ECO:0000244|PDB:4XWH}.
FT   HELIX       632    646       {ECO:0000244|PDB:4XWH}.
FT   TURN        654    659       {ECO:0000244|PDB:4XWH}.
FT   HELIX       666    669       {ECO:0000244|PDB:4XWH}.
FT   HELIX       671    687       {ECO:0000244|PDB:4XWH}.
FT   HELIX       694    710       {ECO:0000244|PDB:4XWH}.
FT   HELIX       723    740       {ECO:0000244|PDB:4XWH}.
SQ   SEQUENCE   743 AA;  82266 MW;  6D8D6A42C7BA7CF3 CRC64;
     MEAVAVAAAV GVLLLAGAGG AAGDEAREAA AVRALVARLL GPGPAADFSV SVERALAAKP
     GLDTYSLGGG GAARVRVRGS TGVAAAAGLH RYLRDFCGCH VAWSGSQLRL PRPLPAVPGE
     LTEATPNRYR YYQNVCTQSY SFVWWDWARW EREIDWMALN GINLALAWSG QEAIWQRVYL
     ALGLTQAEIN EFFTGPAFLA WGRMGNLHTW DGPLPPSWHI KQLYLQHRVL DQMRSFGMTP
     VLPAFAGHVP EAVTRVFPQV NVTKMGSWGH FNCSYSCSFL LAPEDPIFPI IGSLFLRELI
     KEFGTDHIYG ADTFNEMQPP SSEPSYLAAA TTAVYEAMTA VDTEAVWLLQ GWLFQHQPQF
     WGPAQIRAVL GAVPRGRLLV LDLFAESQPV YTRTASFQGQ PFIWCMLHNF GGNHGLFGAL
     EAVNGGPEAA RLFPNSTMVG TGMAPEGISQ NEVVYSLMAE LGWRKDPVPD LAAWVTSFAA
     RRYGVSHPDA GAAWRLLLRS VYNCSGEACR GHNRSPLVRR PSLQMNTSIW YNRSDVFEAW
     RLLLTSAPSL ATSPAFRYDL LDLTRQAVQE LVSLYYEEAR SAYLSKELAS LLRAGGVLAY
     ELLPALDEVL ASDSRFLLGS WLEQARAAAV SEAEADFYEQ NSRYQLTLWG PEGNILDYAN
     KQLAGLVANY YTPRWRLFLE ALVDSVAQGI PFQQHQFDKN VFQLEQAFVL SKQRYPSQPR
     GDTVDLAKKI FLKYYPRWVA GSW
//
